CVKD
Cadrenal Therapeutics, Inc. Common Stock
閉場中RVOL 0.9xDV $108,04620日平均DV $111,831?
Earnings 2026-11-0952W high -93.4%52W low +0.0%Fwd PER 0.1xMarket cap $4MAvg volume 115K
Company Overview
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -1.14 | $0 | -$2M |
| 2026 Q1 | -1.04 | $0 | -$3M |
| 2025 Q4 | -1.41 | $0 | -$3M |
| 2025 Q3 | -1.31 | $0 | -$2M |
| 2025 Q2 | -1.87 | $0 | -$3M |
| 2025 Q1 | -2.09 | $0 | -$5M |
| 2024 Q4 |
